Justine Kent, MD

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-month, Open-label Extension Study

Background: SEP-363856 is a novel non-D2 receptor antagonist, and preclinical data suggest that agonism at trace amine associated receptor 1 (TAAR1) and the serotonin 5-H1A receptor contr...

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Justine Kent , MD;

Antony Loebel , MD;

10/08/2020

Efficacy and Safety of Dasotraline in Adults With Binge-Eating Disorder: A Randomized, Double-blind, Fixed-dose Trial

Background: In a previous flexible dose study, dasotraline, a long-acting dopamine/ norepinephrine reuptake inhibitor, demonstrated significant efficacy in the treatment of binge-eating d...

Joyce Tsai , PhD;

Justine Kent , MD;

Antony Loebel , MD;

Robert Goldman , PhD;

Brad Navia , MD, PhD;

James Hudson , MD;

Carlos Grilo , PhD;

Susan McElroy , MD;

Ling Deng , PhD;

11/22/2019

Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial

Background: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity which has shown efficacy in animal models of psyc...

Antony Loebel , MD;

Justine Kent , MD;

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

11/22/2019

The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Treated with Atypical Antipsychotics

Background: Extrapyramidal symptoms (EPS), including movement disorders, tremors, and muscle contractions are common side effects of atypical antipsychotic (AAP) drugs in patients with sc...

Aditi Kadakia , MS;

Huan Huang , PhD;

Carole Dembek , MS;

Rhys Williams , PhD;

Justine Kent , MD;

Brenna Brady , PhD;

10/08/2020